US Stock Insider Trading | Verastem Discloses 1 Insider Transaction on February 5

K-LinePoet · 2026-02-05T22:09:56+00:00

Verastem (VSTM) disclosed on February 5, 2026, that Director Paterson Dan sold 970 shares on February 4, with a total transaction amount of $6,489.30. Recently, there have been frequent insider trades within the company, including multiple sales by executive Calkins Daniel. Verastem focuses on developing novel anti-cancer drugs.

K-LinePoet

2026-02-05 22:09:56

Abstract generation in progress

On February 5, 2026, Verastem (VSTM) disclosed one insider trading transaction. Director Paterson Dan sold 970 shares on February 4, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Director	Paterson Dan	February 4, 2026	Sell	970	6.69	6489.30
January 14, 2026	Executive	Calkins Daniel	January 12, 2026	Sell	5039	7.16	$36,100
January 14, 2026	Director	Paterson Dan	January 12, 2026	Sell	10,300	7.16	$73,900
December 29, 2025	Executive	Calkins Daniel	December 24, 2025	Sell	80	7.86	628.80
December 18, 2025	Director	Paterson Dan	December 16, 2025	Sell	393	9.14	3592.02
December 18, 2025	Director	Gagnon Robert E., Stuglik Brian M	December 16, 2025	Sell	875	9.14	7997.50
December 12, 2025	Director	Paterson Dan	December 10, 2025	Sell	2000	10.07	$20,100
December 12, 2025	Director	Paterson Dan	December 11, 2025	Sell	2000	10.00	$20,000
December 9, 2025	Director	Paterson Dan	December 5, 2025	Sell	2000	10.61	$21,200
December 9, 2025	Director	Paterson Dan	December 8, 2025	Sell	2000	10.50	$21,000

【Company Information】

Verastem, Inc. was incorporated on August 4, 2010, as a Delaware corporation. The company is a late-stage biopharmaceutical company engaged in conducting registration-directed trials, dedicated to advancing new drugs for patients fighting cancer. The company’s pipeline focuses on novel anti-cancer agents that inhibit key signaling pathways in cancer, which promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.